Question explored with the scientific record
Is wegovy safe
Wegovy is not "safe" in the sense the ads imply. It is a real drug with real benefits and real harms, and the long-term safety picture is thin.
The honest answer depends on who you are. In people with heart disease and a BMI of 27 or more, the SELECT trial of 17,604 patients found semaglutide cut heart attacks, strokes, and heart deaths by about 20% relative to placebo [2][5]. That is a hard outcome, not a lab number, and it is the strongest evidence in this stack. But the same trial found gastrointestinal side effects were the most common problem, worst during dose escalation, and the reviewers noted tolerability at the maintenance dose "may be an issue" [2]. In the broader trials, 30% to 70% of people got GI side effects, mostly early and transient, with 4% to 9% stopping treatment [6].
| What | Number | Source |
|---|---|---|
| Heart attack/stroke/death reduction (SELECT) | ~20% relative | [5] |
| GI side effects across trials | 30%–70% | [6] |
| Stopped treatment for GI effects | 3%–4% | [6] |
| Weight loss, no diabetes (STEP 1) | ~14.9% | [4] |
| Weight loss, with diabetes (STEP 2) | ~9.6% | [4] |
The serious risks are real but rare: pancreatitis, gallbladder disease, retinopathy, kidney problems, and medullary thyroid cancer are all listed [3]. Retinopathy risk may track rapid blood sugar drops [1]. This retrieval does not include a long-term safety trial past a few years, and it does not include the post-marketing picture. That absence is not proof of safety.
My call: for someone with established heart disease and obesity, the benefit is proven and worth weighing against GI misery and rare serious harms. For a healthy person chasing cosmetic weight loss, the risk-benefit math is much weaker and the evidence does not support it. Confidence: moderate.
Sources used 6
-
Long-term Safety Profile of Semaglutide in the Management of Type 2 Diabetes and Obesity
Semaglutide shows overall long-term tolerability in type 2 diabetes and obesity, with dose-dependent gastrointestinal side effects and rare but serious risks like pancreatitis and retinopathy, underscoring the need for extended safety data.
DOI: 10.61173/rvr8p069 -
Semaglutide (Wegovy)
The 2024 CDA-AMC resubmission review of semaglutide 2.4 mg (Wegovy) for chronic weight management in adults with BMI ≥27 kg/m² and established cardiovascular disease is based primarily on the SELECT trial (N=17,604), a phase IIIb randomized, double-blind, placebo-controlled tria…
DOI: 10.51731/cjht.2025.1255 -
Therapeutic Boon or Hidden Bane? Semaglutide for Weight Loss in Non-diabetics
A narrative review concludes that semaglutide achieves substantial weight loss and cardiovascular benefits in nondiabetic patients, but high cost, gastrointestinal and rare serious side effects, and misuse risks require comprehensive obesity-care strategies.
DOI: 10.29328/journal.jcmhs.1001080 -
Wegovy (Semaglutide): A New Weight Loss Drug for Chronic Weight Management
A narrative review synthesizing semaglutide’s weight-loss evidence across the SUSTAIN, PIONEER, and STEP randomized trials (subcutaneous and oral forms) in adults with overweight/obesity, with or without type 2 diabetes, highlighting efficacy, safety, and clinical implications f…
DOI: 10.1136/jim-2021-001952 -
Cardiovascular protection beyond glucose lowering: GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonism in contemporary cardiology
Phenotype-directed GLP-1-based therapy reduces MACE and heart failure events in specific cardiometabolic populations, but tirzepatide is only noninferior to dulaglutide and direct myocardial mechanisms remain unproven.
DOI: 10.3389/fcvm.2026.1926629 -
Efficacy and safety of high‐dose glucagon‐like peptide‐1, glucagon‐like peptide‐1/glucose‐dependent insulinotropic peptide, and glucagon‐like peptide‐1/glucagon receptor agonists in type 2 diabetes
In this systematic review, high-dose GLP-1 RAs and especially tirzepatide increased proportions of patients with type 2 diabetes reaching HbA1c <7% (up to 80%-97%) and weight-loss targets, with gastrointestinal side effects in 30%-70% that were mostly mild and transient.
DOI: 10.1111/dom.14640